1. Home
  2. NDRA vs REVB Comparison

NDRA vs REVB Comparison

Compare NDRA & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

HOLD

Current Price

$6.40

Market Cap

5.5M

Sector

Health Care

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.15

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDRA
REVB
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
5.1M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
NDRA
REVB
Price
$6.40
$1.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
22.8K
65.9K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
84.32
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.92
$0.47
52 Week High
$11.91
$3.62

Technical Indicators

Market Signals
Indicator
NDRA
REVB
Relative Strength Index (RSI) 76.66 40.50
Support Level $4.22 $1.06
Resistance Level $6.95 $1.20
Average True Range (ATR) 0.47 0.10
MACD 0.12 -0.00
Stochastic Oscillator 100.00 29.32

Price Performance

Historical Comparison
NDRA
REVB

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: